An Exelixis Product for the Clinical Management of HCC
Supported by: An Exelixis Product for the Clinical Management of HCC
Presenter:
Julio A. Gutierrez, MD, MS
Terlipressin and Albumin Use in Hepatorenal Syndrome
Supported by: Mallinckrodt Pharmaceuticals
Presenter:
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
NIS4 and NIS2+: Promising Blood-based Biomarkers for NASH Clinical Trials and Patient Care
Supported by: Labcorp
NIS4® is a blood-based test designed to effectively identify patients with at-risk metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The more recently developed NIS2+™ is an optimized version of NIS4® that was
Taking Current PBC Treatment Further
Supported by: Intercept Pharmaceuticals, Inc.
Join us for an informative presentation that discusses taking treatment for Primary Biliary Cholangitis (PBC) a step further. Learn about an approved therapy for patients with PBC.
Presenters:
Kris Kowdley,
Clinical Review: A Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria
Supported by: Alnylam Pharmaceuticals
AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks of which the cardinal symptom is severe, diffuse abdominal pain. This presentation will provide a disease overview an
Patient-Based Care in Primary Biliary Cholangitis: Reassessing the Management Pathway
Supported by: Ipsen
In primary biliary cholangitis, it is important to look beyond the liver to make meaningful improvements for patients, so how can we optimize regular disease monitoring alongside the impact of symptoms on patients’ lives? Join us to
Spotlight on MASH (Formerly NASH): Exploring the Pathophysiology and Metabolic Impairments of a Progressive Liver Disease
Supported by: Novo Nordisk
Join us as we review the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH, non-alcoholic steatohepatitis), including the impact of underlying metabolic comorbidities. We will als
cT1 as a Monitoring Tool in Metabolic Dysfunction Associated Steatotic Liver Disease
- Read more about cT1 as a Monitoring Tool in Metabolic Dysfunction Associated Steatotic Liver Disease
Supported by: Perspectum
In this session we will introduce cT1, a well-established biomarker in liver disease derived from MRI technology. cT1 has played a pivotal role in numerous clinical trials focused on Steatotic Liver Disease, proving its effectiv